Shares of Unum Therapeutics were on a downward turn this week after the Food and Drug Administration suspended a trial of one of the company’s cancer drugs on Tuesday. The FDA suspended the trial of cancer drug ACTR087, after a patient had experienced serious side effects which included Grade 3 neurotoxicity and cytomegalovirus (CMV) infection, … Continue reading “Dangerous Side Effects Prompts FDA to Suspend Unum Therapeutics’ Cancer Drug Trial”
